Aclarion, Inc. (Nasdaq: ACON, ACONW) reported first quarter 2026 results on April 30, 2026, highlighting a 196% year-over-year increase in Nociscan scan volumes, reflecting accelerating clinical adoption of its biomarker and AI-driven platform for identifying the source of chronic low back pain. The company also achieved 64% sequential growth from Q4 2025, driven by new account activation and higher utilization within existing sites.
CEO Brent Ness described the quarter as a clear inflection point, emphasizing that the company is still in early stages of commercializing Nociscan into a large market. Approximately 5.8 million lumbar MRIs are performed annually in the U.S. for low back pain, representing what Aclarion believes is a potential $2 billion market opportunity for technologies like Nociscan that provide objective evaluation of discogenic pain.
Reimbursement progress in the U.K. has been a key catalyst, with Nociscan now reimbursed by Vitality, AXA, and Aviva, three of the four largest private insurers in the U.K. Aclarion also launched a targeted direct-to-patient campaign in the U.K., featuring a video with Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic, available here. In the U.S., the company continues to engage payers through its Nociscan Reimbursement Program.
On the clinical front, the CLARITY randomized trial is ongoing, with a preliminary internal readout expected in the second half of 2026 and public disclosure of early interim results anticipated in late Q4 2026. Aclarion also strengthened its intellectual property portfolio with a newly issued patent covering AI in workflows of future products, bringing its total to 64 issued and pending patents worldwide.
Aclarion maintains a strong financial position with $19.0 million in cash, no debt, and a clean capital structure. As of March 31, 2026, there were 2,444,871 common shares outstanding. The company recently announced a $2.5 million share repurchase program and believes its cash runway extends into the second half of 2027.
For more news from Aclarion, visit their latest news page. To find a Nociscan center, view the site map here.
